Johnson & Johnson

10/28/2024 | Press release | Distributed by Public on 10/28/2024 05:32

TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn's disease